• MediciNova released topline Phase 2 results for MN-001 in NAFLD with high triglycerides tied to type 2 diabetes.
• The study showed favorable signals on cholesterol-related measures, with mixed effects on other disease indicators that fell short of primary goals.
• MN-001 was well tolerated, with no drug-related serious adverse events reported.
• Further data analyses are underway to guide next steps for the program.
• Topline results for the COMBAT-ALS trial of MN-166 in ALS are expected by year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120600PRIMZONEFULLFEED9843605) on October 12, 2026, and is solely responsible for the information contained therein.